While progress has been made using artificial intelligence (AI) and specialized techniques to identify potent in vitro S protein binders (Cao et al., 2020), development of effective, orally available, broad-spectrum therapeutics that can be used to confront COVID-19 and enable wider therapeutic access across large populations remain elusive. Here, PROS1 is linked to COVID-19.